STD
Information Center > STD
News > Prevention of HPV
STD Information Center Menu: |
|
Prevention
of Genital Human Papillomavirus Infection
Report
to Congress Page 5
Reference List
(1) Cates W, Jr. Estimates of the incidence
and prevalence of sexually transmitted diseases in
the United States. American Social Health Association
Panel. Sexually Transmitted Diseases 1999; 26(4:Suppl):Suppl-7.
(2) NIH Consensus Statement Online 1996
April 1-3 [October 28, 2003]. pp 1-38.
(3) World Health
Organization.
IARC Monograph on the Evaluation of Carcinogenic Risks
to Humans: Human Papillomaviruses. [64]. 1995. Lyons,
IARC.
(4) Daling JR, Weiss NS, Klopfenstein
LL, Cochran LE, Chow WH, Daifuku R. Correlates of homosexual
behavior
and the incidence of anal cancer. JAMA 1982; 247(14):1988-1990.
(5) Daling JR, Weiss NS, Hislop TG, Maden
C, Coates RJ, Sherman KJ et al. Sexual practices, sexually
transmitted
diseases, and the incidence of anal cancer. New England
Journal of Medicine 1987; 317(16):973-977.
(6) Holly
EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ,
Kristiansen JJ. Anal cancer incidence: genital warts,
anal fissure or fistula, hemorrhoids, and smoking.
Journal of the National Cancer Institute 1989; 81(22):1726-1731.
(7) Koblin BA, Hessol NA, Zauber AG,
Taylor PE, Buchbinder SP, Katz MH et al. Increased
incidence of cancer among
homosexual men, New York City and San Francisco, 1978-1990.
American Journal of Epidemiology 1996; 144(10):916-923.
(8) Ries L, Kosery C, Hankey B, MillerB,
Clegg L, Edwards B. SEER Cancer Statistics Review 1973-1996.
Bethesda,
MD: National Cancer Institute, 1999.
(9) Herrero R,
Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram
P et al. Human papillomavirus and oral cancer: the
International Agency for Research on Cancer multicenter
study. Journal of the National Cancer Institute 2003;
95(23):1772-1783.
(10) Syrjanen KJ. HPV infections
and oesophageal cancer. Journal of Clinical Pathology
2002; 55(10):721-728.
(11) Cuzick J. Human papillomavirus
infection of the prostate. Cancer Surveys 1995; 23:91-95.
(12) Adami HO, Kuper H, Andersson SO,
Bergstrom R, Dillner J. Prostate cancer risk and serologic
evidence
of human papilloma virus infection: a population-based
case-control study. Cancer Epidemiology, Biomarkers & Prevention
2003; 12(9):872-875.
(13) Rosenblatt KA, Carter JJ,
Iwasaki LM, Galloway DA, Stanford JL. Serologic evidence
of human papillomavirus 16 and 18 infections and risk
of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention
2003; 12(8):763-768.
(14) Division of STD Prevention. Prevention
of Genital HPV Infection and Sequelae: Report of an
External Consultants' Meeting. 1999. Atlanta, GA.,
Department of Health and Human Services, Atlanta: Centers
for Disease Control and Prevention (CDC).
(15) Koutsky
LA, Galloway DA, Holmes KK. Epidemiology of genital
human papillomavirus infection. Epidemiologic Reviews
1988; 10:122-163.
(16) Myers ER, McCrory DC, Nanda
K, Bastian L, Matchar DB. Mathematical model for the
natural history of human papillomavirus infection and
cervical carcinogenesis. American Journal of Epidemiology
2000; 151(12):1158-1171.
(17) Weinstock H, Berman S,
cates W. Sexually Transmitted Infections in American
Youth: Incidence and Prevalence Estimates, 2000. Perspectives
on Sexual and Reproductive Health. In press.
(18) Fairley
CK, Chen S, Tabrizi SN, Leeton K, Quinn MA, Garland
SM. The absence of genital human papillomavirus DNA
in virginal women. International Journal of STD & AIDS
1992; 3(6):414-417.
(19) Rylander E, Ruusuvaara L,
Almstromer MW, Evander M, Wadell G. The absence of
vaginal human papillomavirus 16 DNA in women who have
not experienced sexual intercourse. Obstetrics & Gynecology
1994; 83(5:Pt 1):1-7.
(20) Koutsky LA, Kiviat NB. Genital
human papillomavirus. In: Holmes KK, Sparling PF,
Mardh PA et al, editors. Sexually Transmitted Diseases.
New
York: McGraw-Hill, 1999: 347-359.
(21) Winer RL,
Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA.
Genital
human papillomavirus infection: incidence and risk
factors in a cohort of female university students.
American Journal of Epidemiology 2003; 157(3):218-226.
(22) Baken LA, Koutsky LA, Kuypers J,
Kosorok MR, Lee SK, Kiviat NB et al. Genital human
papillomavirus
infection
among male and female sex partners: prevalence
and type-specific concordance. Journal of Infectious
Diseases 1995; 171(2):429-432.
(23) Bauer HM, Ting
Y, Greer
CE, Chambers JC, Tashiro CJ, Chimera J et al.
Genital human papillomavirus infection in female
university students as determined by a PCR-based method.
JAMA
1991; 265(4):472-477.
(24) Bauer HM, Hildesheim
A,
Schiffman MH, Glass AG, Rush BB, Scott DR
et al. Determinants of genital human papillomavirus
infection
in low-risk
women in Portland, Oregon. Sexually Transmitted
Diseases 1993; 20(5):274-278.
(25) Ley C, Bauer
HM, Reingold
A, Schiffman MH, Chambers JC, Tashiro CJ
et
al. Determinants of genital human papillomavirus
infection in young
women. Journal of the National Cancer Institute
1991; 83(14):997-1003.
(26) Peyton CL, Gravitt PE, Hunt WC,
Hundley RS, Zhao M, Apple RJ et al. Determinants of
genital human papillomavirus detection in a US population.
Journal of Infectious Diseases 2001; 183(11):1554-1564.
(27) Wheeler CM, Parmenter CA, Hunt WC,
Becker TM, Greer CE, Hildesheim A et al. Determinants
of genital
human papillomavirus infection among cytologically
normal women attending the University of New Mexico
student health center. Sexually Transmitted Diseases
1993; 20(5):286-289.
(28) Ho GY, Bierman R, Beardsley
L, Chang CJ, Burk RD. Natural history of cervicovaginal
papillomavirus infection in young women. New England
Journal of Medicine 1998; 338(7):423-428.
(29)
Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D,
Papenfuss
MR et al. Incidence, prevalence, and clearance
of type-specific human papillomavirus infections:
The Young Women's
Health Study. Journal of Infectious Diseases
2002; 186(4):462-469.
(30) Burk RD, Kelly P, Feldman
J,
Bromberg J, Vermund SH, DeHovitz JA et al. Declining
prevalence
of cervicovaginal human papillomavirus infection
with age is independent of other risk factors.
Sexually
Transmitted Diseases 1996; 23(4):333-341.
(31)
Moscicki AB, Hills N, Shiboski S, Powell K, Jay
N, Hanson
E
et al. Risks for incident human papillomavirus
infection and low-grade squamous intraepithelial
lesion development
in young females. JAMA 2001; 285(23):2995-3002.
(32) Rousseau MC, Pereira JS, Prado JC,
Villa LL, Rohan TE, Franco EL. Cervical coinfection
with
human
papillomavirus
(HPV) types as a predictor of acquisition
and persistence
of HPV infection. Journal of Infectious
Diseases 2001; 184(12):1508-1517.
(33) Franco EL, Villa
LL, Sobrinho
JP, Prado JM, Rousseau MC, Desy M et
al. Epidemiology of acquisition and clearance of cervical
human
papillomavirus infection in women from a
high-risk
area for cervical
cancer. Journal of Infectious Diseases
1999;
180(5):1415-1423.
(34) Herrero R, Hildesheim
A, Bratti C, Sherman
ME, Hutchinson M, Morales J et al. Population-based
study
of human papillomavirus infection and
cervical neoplasia in rural Costa Rica. Journal of
the
National Cancer
Institute 2000; 92(6):464-474.
(35)
Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony
JB, Lytwyn A, Chong S et
al. Incidence, clearance and predictors
of human
papillomavirus infection in women.[comment].
CMAJ Canadian Medical
Association Journal 2003; 168(4):421-425.
(36) Woodman CB, Collins S, Winter H,
Bailey A,
Ellis J, Prior
P et al. Natural history of cervical
human papillomavirus
infection in young women: a longitudinal
cohort study. Lancet 2001; 357(9271):1831-1836.
(37) Franco EL, Duarte-Franco E, Ferenczy
A. Cervical cancer: epidemiology, prevention and the
role of human papillomavirus infection. CMAJ Canadian
Medical Association Journal 2001; 164(7):1017-1025.
(38) Fairley CK, Chen S, Ugoni A, Tabrizi
SN, Forbes A, Garland SM. Human papillomavirus infection
and its
relationship to recent and distant sexual partners.
Obstetrics & Gynecology 1994; 84(5):755-759.
(39)
Davidson M, Schnitzer PG, Bulkow LR, Parkinson AJ,
Schloss ML, Fitzgerald MA et al. The prevalence of
cervical infection with human papillomaviruses and
cervical dysplasia in Alaska Native women. Journal
of Infectious Diseases 1994; 169(4):792-800.
(40) Fairley
CK, Chen S, Tabrizi SN, McNeil J, Becker G, Walker
R et al. Prevalence of HPV DNA in cervical specimens
in women with renal transplants: a comparison with
dialysis-dependent patients and patients with renal
impairment. Nephrology Dialysis Transplantation 1994;
9(4):416-420.
(41) Moscicki AB, Ellenberg JH, Vermund
SH, Holland CA, Darragh T, Crowley-Nowick PA et al.
Prevalence of and risks for cervical human papillomavirus
infection and squamous intraepithelial lesions in adolescent
girls: impact of infection with human immunodeficiency
virus. Archives of Pediatrics & Adolescent Medicine
2000; 154(2):127-134.
(42) Jamieson DJ, Duerr A, Burk
R, Klein RS, Paramsothy P, Schuman P et al. Characterization
of genital human papillomavirus infection in women
who have or who are at risk of having HIV infection.
American Journal of Obstetrics & Gynecology 2002;
186(1):21-27.
(43) Sun XW, Kuhn L, Ellerbrock TV, Chiasson
MA, Bush TJ, Wright TC, Jr. Human papillomavirus infection
in women infected with the human immunodeficiency virus.
New England Journal of Medicine 1997; 337(19):1343-1349.
(44) Aynaud O, Poveda JD, Huynh B, Guillemotonia
A, Barrasso R. Frequency of herpes simplex virus, cytomegalovirus
and human papillomavirus DNA in semen. International
Journal of STD & AIDS 2002; 13(8):547-550.
(45)
Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen
M, Vaught LC, Kornegay JR et al. Human papillomavirus
infection in men attending a sexually transmitted
disease
clinic. Journal of Infectious Diseases 2003; 187(7):1064-1070.
(46) Castellsague X, Bosch FX, Munoz
N, Meijer CJ, Shah KV, de Sanjose S et al. Male circumcision,
penile
human papillomavirus infection, and cervical cancer
in female partners. New England Journal of Medicine
2002; 346(15):1105-1112.
(47) Fife KH, Coplan PM,
Jansen KU, DiCello AC, Brown DR, Rojas C et al.
Poor sensitivity
of polymerase chain reaction assays of genital
skin swabs and urine to detect HPV 6 and 11 DNA in
men.
Sexually Transmitted Diseases 2003; 30(3):246-248.
(48) Hippelainen M, Syrjanen S, Hippelainen
M, Koskela H, Pulkkinen J, Saarikoski S et al. Prevalence
and risk factors of genital human papillomavirus (HPV)
infections in healthy males: a study on Finnish conscripts.
Sexually Transmitted Diseases 1993; 20(6):321-328.
(49) Lazcano-Ponce E, Herrero R, Munoz
N, Hernandez-Avila M, Salmeron J, Leyva A et al. High
prevalence of human
papillomavirus infection in Mexican males: comparative
study of penile-urethral swabs and urine samples. Sexually
Transmitted Diseases 2001; 28(5):277-280.
(50) Olatunbosun
O, Deneer H, Pierson R. Human papillomavirus DNA detection
in sperm using polymerase chain reaction. Obstetrics & Gynecology
2001; 97(3):357-360.
(51) Rintala MA, Pollanen PP,
Nikkanen VP, Grenman SE, Syrjanen SM. Human papillomavirus
DNA is found in the vas deferens. Journal of Infectious
Diseases 2002; 185(11):1664-1667.
(52) Svare EI, Kjaer
SK, Worm AM, Osterlind A, Meijer CJ, van den Brule
AJ. Risk factors for genital HPV DNA in men resemble
those found in women: a study of male attendees at
a Danish STD clinic. Sexually Transmitted Infections
2002; 78(3):215-218.
(53) Wikstrom A, Popescu C, Forslund
O. Asymptomatic penile HPV infection: a prospective
study. International Journal of STD & AIDS 2000;
11(2):80-84.
(54) Van Doornum GJ, Prins M, Juffermans
LH, Hooykaas C, van den Hoek JA, Coutinho RA et al.
Regional distribution and incidence of human papillomavirus
infections among heterosexual men and women with
multiple sexual partners: a prospective study. Genitourinary
Medicine 1994; 70(4):240-246.
(55) Weaver BA, Feng
Q, Holmes KK, Kiviat N, Lee S, Meyer C et al. Evaluation
of Genital Sites and Sampling Techniques for HPV
DNA
Detection in Men. Journal of Infectious Diseases.
In press.
(56) Perez J, Trigg B, Wheeler C. Detection
of Genital Human Papillomavirus (HPV) in Men
Using Different Sampling Strategies. [Abstract P 090]
International Papillomavirus Conference, October
4-9,
2002, Paris,
France.
(57) Weaver B, Feng Q, Kiviat N, Holmes
K, Lee S, Meyer C et al. Evaluation of genital
sampling techniques for HPV DNA detection. [Abstract
O019]
International
Papillomavirus Conference October 4-9, 2002.
Paris, France.
(58) Carter JJ, Koutsky LA, Hughes
JP, Lee
SK, Kuypers J, Kiviat N et al. Comparison
of human
papillomavirus types 16, 18, and 6 capsid
antibody responses following incident infection. Journal
of Infectious Diseases 2000; 181(6):1911-1919.
(59) Wideroff L, Schiffman M, Haderer
P, Armstrong A, Greer CE, Manos MM et al. Seroreactivity
to human papillomavirus types 16, 18, 31, and 45 virus-like
particles in a case-control study of cervical squamous
intraepithelial lesions. Journal of Infectious Diseases
1999; 180(5):1424-1428.
(60) Wideroff L, Schiffman
MH, Hoover R, Tarone RE, Nonnenmacher B, Hubbert N
et al. Epidemiologic determinants of seroreactivity
to human papillomavirus (HPV) type 16 virus-like particles
in cervical HPV-16 DNA-positive and-negative women.
Journal of Infectious Diseases 1996; 174(5):937-943.
(61) Stone KM, Karem KL, Sternberg MR,
McQuillan GM, Poon AD, Unger ER et al. Seroprevalence
of Human Papillomavirus
Type 16 Infection in the United States. Journal of
Infectious Diseases 2002; 186.
(62) Slavinsky J, III,
Kissinger P, Burger L, Boley A, DiCarlo RP, Hagensee
ME. Seroepidemiology of low and high oncogenic risk
types of human papillomavirus in a predominantly male
cohort of STD clinic patients. International Journal
of STD & AIDS 2001; 12(8):516-523.
(63) Chuang
TY, Perry HO, Kurland LT, Ilstrup DM. Condyloma acuminatum
in Rochester, Minn., 1950-1978. I. Epidemiology and
clinical features. Archives of Dermatology 1984;
120(4):469-475.
(64) Koutsky L. Epidemiology of genital
human papillomavirus
infection. American Journal of Medicine 1997; 102(5A):3-8.
(65) Armstrong LR, Preston EJ, Reichert
M, Phillips DL, Nisenbaum R, Todd NW et al. Incidence
and prevalence
of recurrent respiratory papillomatosis among children
in Atlanta and Seattle. Clinical Infectious Diseases
2000; 31(1):107-109.
(66) ACS. Cancer Facts and
Figures 2003.
(67) Molano M, Van den BA, Plummer
M, Weiderpass
E, Posso H, Arslan A et al. Determinants of
clearance of human papillomavirus infections in Colombian
women with normal cytology: a population-based,
5-year
follow-up study. American Journal of Epidemiology
2003;
158(5):486-494.
(68) Moscicki AB, Shiboski S, Broering
J, Powell K, Clayton L, Jay N et al. The natural history
of human papillomavirus infection as measured by
repeated DNA
testing in adolescent and young women. Journal
of
Pediatrics 1998; 132(2):277-284.
(69) Ho GY,
Burk RD, Klein S,
Kadish AS, Chang CJ, Palan P et al. Persistent
genital human papillomavirus infection as a
risk factor
for
persistent cervical dysplasia. Journal
of the
National Cancer Institute 1995; 87(18):1365-1371.
(70) Hildesheim
A, Schiffman MH, Gravitt PE, Glass AG,
Greer CE, Zhang T et al. Persistence of type-specific
human papillomavirus infection among cytologically
normal
women. Journal
of Infectious Diseases 1994; 169(2):235-240.
(71) Schlecht NF, Platt RW, Duarte-Franco
E, Costa MC, Sobrinho JP, Prado JC et al. Human papillomavirus
infection and time to progression and regression of
cervical intraepithelial neoplasia. Journal of the
National Cancer Institute 2003; 95(17):1336-1343.
(72)
Koutsky LA, Holmes KK, Critchlow CW, Stevens CE,
Paavonen J, Beckmann AM et al. A cohort study of the
risk of
cervical intraepithelial neoplasia grade 2 or 3 in
relation to papillomavirus infection. New England
Journal of Medicine 1992; 327(18):1272-1278.
(73) Ostor
AG.
Natural history of cervical intraepithelial neoplasia:
a critical review. International Journal of Gynecological
Pathology 1993; 12(2):186-192.
(74) Munoz N. Human
papillomavirus and cancer: the epidemiological
evidence. Journal of Clinical Virology 2000; 19(1-2):1-5.
(75)
Munoz N, Bosch FX. Epidemiology of cervical cancer.
IARC Scientific Publications 1989;(94):9-39.
(76) Smith JS, Green J, Berrington dG,
Appleby P, Peto J, Plummer
M et al. Cervical cancer and use of hormonal
contraceptives:
a systematic review. Lancet 2003; 361(9364):1159-1167.
(77) Castellsague X, Bosch FX, Munoz
N. Environmental co-factors in HPV carcinogenesis.
Virus Research
2002; 89(2):191-199.
(78) Castellsague X, Munoz
N. Chapter
3: Cofactors in human papillomavirus carcinogenesis--role
of parity, oral contraceptives, and tobacco
smoking. Journal of the National Cancer Institute
Monographs 2003;(31):20-28.
(79) Hildesheim A, Herrero
R,
Castle PE, Wacholder S, Bratti MC, Sherman
ME et
al. HPV
co-factors related to the development of
cervical cancer: results
from a population-based study in Costa
Rica. British Journal of Cancer 2001; 84(9):1219-1226.
(80) Sedjo
RL, Fowler BM, Schneider A, Henning
SM, Hatch
K, Giuliano AR. Folate, vitamin B12, and
homocysteine status. findings
of no relation between human papillomavirus
persistence and cervical dysplasia. Nutrition
2003; 19(6):497-502.
(81) Castle PE, Giuliano AR. Chapter
4: Genital tract infections, cervical inflammation,
and
antioxidant nutrients--assessing their roles
as human papillomavirus
cofactors. [Review] [50 refs]. Journal
of
the National
Cancer Institute Monographs 2003;(31):29-34.
(82) Smith JS, Munoz N, Herrero R, Eluf-Neto
J, Ngelangel C, Franceschi
S et al. Evidence for Chlamydia trachomatis
as a
human papillomavirus cofactor in the
etiology of invasive cervical cancer in Brazil and
the
Philippines. Journal
of Infectious Diseases 2002; 185(3):324-331.
(83)
Schiffman
M, Kjaer SK. Chapter 2: Natural
history of anogenital
human papillomavirus infection
and neoplasia. Journal of the National Cancer Institute
Monographs
2003;(31):14-19.
(84) Karlsson R, Jonsson M, Edlund K,
Evander M, Gustavsson A, Boden E et al. Lifetime number
of partners as the only independent risk factor for
human papillomavirus infection: a population-based
study. Sexually Transmitted Diseases 1995; 22(2):119-127.
(85) Castle PE, Shields T, Kirnbauer
R, Manos MM, Burk RD, Glass AG et al. Sexual behavior,
human papillomavirus
type 16 (HPV 16) infection, and HPV 16 seropositivity.
Sexually Transmitted Diseases 2002; 29(3):182-187.
(86) Burk RD, Ho GY, Beardsley L, Lempa
M, Peters M, Bierman R. Sexual behavior and partner
characteristics
are the predominant risk factors for genital human
papillomavirus infection in young women. Journal of
Infectious Diseases 1996; 174(4):679-689.
(87) Jamison
JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas
JM, Jr. Spectrum of genital human papillomavirus
infection in a female adolescent population. Sexually
Transmitted
Diseases 1995; 22(4):236-243.
(88) Coutlee F, Trottier
AM, Ghattas G, Leduc R, Toma E, Sanche G et al. Risk
factors for oral human papillomavirus in adults infected
and not infected with human immunodeficiency virus.
Sexually Transmitted Diseases 1997; 24(1):23-31.
(89)
Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM.
Hand-genital transmission of genital warts? An analysis
of prevalence data. Epidemiology & Infection 1995;
115(1):169-176.
(90) Marrazzo JM, Stine K, Koutsky
LA. Genital human papillomavirus infection in women
who have sex with women: a review. American Journal
of Obstetrics & Gynecology 2000; 183(3):770-774.
(91) Watts DH, Koutsky LA, Holmes KK,
Goldman D, Kuypers J, Kiviat NB et al. Low risk of
perinatal transmission
of human papillomavirus: results from a prospective
cohort study. American Journal of Obstetrics & Gynecology
1998; 178(2):365-373.
(92) af G, V, Eklund C, Wang
Z, Sapp M, Schiller JT, Dillner J et al. A survey of
seroprevalence of human papillomavirus types 16, 18
and 33 among children. International Journal of Cancer
1999; 80(4):489-493.
(93) Ferenczy A, Bergeron C, Richart
RM. Human papillomavirus DNA in fomites on objects
used for the management of patients with genital human
papillomavirus infections. Obstetrics & Gynecology
1989; 74(6):950-954.
(94) Roden RB, Lowy DR, Schiller
JT. Papillomavirus is resistant to desiccation. Journal
of Infectious Diseases 1997; 176(4):1076-1079.
(95)
Bergeron C, Ferenczy A, Richart R. Underwear: contamination
by human papillomaviruses. American Journal of Obstetrics & Gynecology
1990; 162(1):25-29.
(96) Ferenczy A, Bergeron C, Richart
RM. Carbon dioxide laser energy disperses human papillomavirus
deoxyribonucleic acid onto treatment fields. American
Journal of Obstetrics & Gynecology 1990; 163(4:Pt
1):t-4.
(97) Eddy DM. Screening for cervical
cancer. Annals of Internal Medicine 1990; 113(3):214-226.
(98)
Kiviat N, Koutsky L, Paavonen J. Cervical Neoplasia
and Other STD-Related Genital Tract Neoplasias. Sexually
Transmitted Diseases. 3rd Edition. New York: McGraw-Hill,
1999: 811-832.
(99) Garnett GP, Anderson RM. Sexually
transmitted diseases and sexual behavior: insights
from mathematical models. Journal of Infectious Diseases
1996; 174:Suppl-61.
(100) Beutner KR, Reitano MV, Richwald
GA, Wiley DJ. External genital warts: report of the
American Medical Association Consensus Conference.
AMA Expert Panel on External Genital Warts. Clinical
Infectious Diseases 1998; 27(4):796-806.
(101) Abba
MC, Mouron SA, Gomez MA, Dulout FN, Golijow CD. Association
of human papillomavirus viral load with HPV16 and
high-grade intraepithelial lesion. International Journal
of Gynecological
Cancer 2003; 13(2):154-158.
(102) Tyring SK, Arany
I, Stanley MA, Tomai MA, Miller RL, Smith MH et al.
A randomized, controlled, molecular study of condylomata
acuminata clearance during treatment with imiquimod.
Journal of Infectious Diseases 1998; 178(2):551-555.
(103) Costa S, De Simone P, Venturoli
S, Cricca M, Zerbini ML, Musiani M et al. Factors predicting
human
papillomavirus clearance in cervical intraepithelial
neoplasia lesions treated by conization. Gynecologic
Oncology 2003; 90(2):358-365.
(104) Elfgren K, Jacobs
M, Walboomers JM, Meijer CJ, Dillner J. Rate of human
papillomavirus clearance after treatment of cervical
intraepithelial neoplasia. Obstetrics & Gynecology
2002; 100(5:Pt 1):t-71.
(105) Bollen LJ, Tjong AHS,
van d, V, Mol BW, ten Kate FW, ter Schegget J et
al. Prediction of recurrent and residual cervical dysplasia
by human papillomavirus detection among patients
with
abnormal cytology. Gynecologic Oncology 1999; 72(2):199-201.
(106) Bodner K, Bodner-Adler B, Wierrani
F, Kimberger O, Denk C, Grunberger W. Is therapeutic
conization
sufficient to eliminate a high-risk HPV infection
of the uterine cervix? A clinicopathological analysis.
Anticancer Research 2002; 22(6B):3733-3736.
(107) Jain
S, Tseng CJ, Horng SG, Soong YK, Pao CC. Negative
predictive value of human papillomavirus test following
conization
of the cervix uteri. Gynecologic Oncology 2001; 82(1):177-180.
28 (108)
Kjellberg L, Wadell G, Bergman F, Isaksson M, Angstrom
T, Dillner J. Regular disappearance of the human
papillomavirus genome after conization of cervical
dysplasia by carbon dioxide laser. American Journal
of Obstetrics & Gynecology 2000; 183(5):1238-1242.
(109) Kucera E, Sliutz G, Czerwenka
K, Breitenecker G, Leodolter S, Reinthaller A. Is
high-risk human
papillomavirus infection associated with cervical
intraepithelial neoplasia eliminated after conization
by large-loop excision of the transformation zone?
European Journal of Obstetrics, Gynecology, & Reproductive
Biology 2001; 100(1):72-76.
(110) Nagai Y, Maehama
T, Asato T, Kanazawa K. Persistence of human papillomavirus
infection after therapeutic conization for CIN
3: is it an alarm for disease recurrence? Gynecologic
Oncology 2000; 79(2):294-299.
(111) Lin CT, Tseng
CJ, Lai CH, Hsueh S, Huang KG, Huang HJ et al. Value
of human papillomavirus deoxyribonucleic acid testing
after conization in the prediction of residual disease
in the subsequent hysterectomy specimen. American
Journal of Obstetrics & Gynecology 2001; 184(5):940-945.
(112) Ferenczy A, Mitao M, Nagai N,
Silverstein SJ, Crum CP. Latent papillomavirus and
recurring genital
warts. New England Journal of Medicine 1985; 313(13):784-788.
(113) Colgan TJ, Percy ME, Suri M,
Shier RM, Andrews DF, Lickrish GM. Human papillomavirus
infection
of morphologically normal cervical epithelium adjacent
to squamous dysplasia and invasive carcinoma.
Human Pathology 1989; 20(4):316-319.
(114) Mitchell MF,
Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris
H, Silva E. A randomized clinical trial of cryotherapy,
laser vaporization, and loop electrosurgical excision
for treatment of squamous intraepithelial lesions
of the cervix. Obstetrics & Gynecology 1998;
92(5):737-744.
(115) Wright TC, Jr., Cox JT, Massad
LS, Twiggs LB, Wilkinson EJ, ASCCP-Sponsored Consensus
Conference. 2001 Consensus Guidelines for the management
of women with cervical cytological abnormalities.
JAMA 2002; 287(16):2120-2129.
(116) Krebs HB, Helmkamp
BF. Treatment failure of genital condylomata acuminata
in women: role of the male sexual partner. American
Journal of Obstetrics & Gynecology 1991; 165(2):337-339.
(117) National Institute of Allergy
and Infectious Diseases. Workshop Summary: Scientific
Evidence on
Condom Effectiveness for Sexually Transmitted Disease
(STD) Prevention.: 2001.
(118) Manhart LE, Koutsky
LA. Do condoms prevent genital HPV infection, external
genital warts, or cervical neoplasia? A meta-analysis.
Sexually Transmitted Diseases 2002; 29(11):725-735.
(119) Baeten JM, Nyange PM, Richardson
BA, Lavreys L, Chohan B, Martin HL, Jr. et al. Hormonal
contraception and risk of sexually transmitted disease
acquisition: results from a prospective study. American
Journal of Obstetrics & Gynecology 2001; 185(2):380-385.
(120) Radcliffe KW, Ahmad S, Gilleran
G, Ross JD. Demographic and behavioural profile of
adults infected
with chlamydia: a case-control study. Sexually
Transmitted Infections 2001; 77(4):265-270.
(121) Wald A, Langenberg
D, Kexel E, Izu A, Ashley R, Corey L. [abstract
B9E] National STD Prevention Conference, San Diego,
CA,
March 4-7, 2002. 3-4-0002.
(122) Wald A, Langenberg
AG, Link K, Izu AE, Ashley R, Warren T et al. Effect
of condoms on reducing the transmission of herpes
simplex virus type 2 from men to women. JAMA 2001;
285(24):3100-3106.
(123) Warner L, Newman DR, Austin
HA, Kamb ML, Douglas JM, Malotte CK et al. Condom
Effectiveness for Reducing Transmission of Gonorrhea
and Chlamydia: The Importance of Assessing Partner
Infection Status. American Journal of Epidemiology.
In press.
(124) Williams KM, Wingood GM, DiClemente
RJ, Crosby RA, Hubbard MD, Liau A et al. Prevalence
and correlates of Chlamydia trachomatis among sexually
active African-American adolescent females. Preventive
Medicine 2002; 35(6):593-600.
(125) Lytle CD, Duff
JE, Fleharty B, Bidinger RL, Cyr WH, Routson LB.
A sensitive method for evaluating condoms as virus
barriers. Journal of AOAC International 1997; 80(2):319-324.
(126) Lytle CD, Routson LB, Seaborn
GB, Dixon LG, Bushar HF, Cyr WH. An in vitro evaluation
of condoms
as barriers to a small virus. Sexually Transmitted
Diseases 1997; 24(3):161-164.
(127) Kennedy L, Buntine
DW, O'Connor D, Frazer IH. Human papillomavirus--a
study of male sexual partners. Medical Journal
of Australia 1988; 149(6):309-311.
(128) Krebs HB, Schneider
V. Human papillomavirus-associated lesions of the
penis: colposcopy, cytology, and histology. Obstetrics & Gynecology
1987; 70(3:Pt 1):t-304.
(129) Schultz RE, Miller
JW, MacDonald GR, Auman JR, Peterson NR, Ward BE
et al. Clinical and molecular evaluation of acetowhite
genital lesions in men. Journal of Urology 1990;
143(5):920-923.
(130) Zenilman JM, Weisman CS, Rompalo
AM, Ellish N, Upchurch DM, Hook EW, III et al.
Condom use to prevent incident STDs: the validity
of self-reported
condom use. Sexually Transmitted Diseases 1995; 22(1):15-21.
(131) Weir SS, Feldblum PJ. Condom
use to prevent incident STDs. Sexually Transmitted
Diseases 1996; 23(1):76-77.
(132) Galavotti C, Cabral
R, Beeker C. Condom use to prevent incident STDs.
Sexually Transmitted Diseases 1996; 23(1):77-79.
(133) Turner CF, Miller HG. Zenilman's
anomaly reconsidered: fallible reports, ceteris paribus,
and other hypotheses.
Sexually Transmitted Diseases 1997; 24(9):522-527.
(134) Peterman TA, Lin LS, Newman DR,
Kamb ML, Bolan G, Zenilman J et al. Does measured
behavior reflect
STD risk? An analysis of data from a randomized
controlled behavioral intervention study. Project
RESPECT Study
Group. Sexually Transmitted Diseases 2000; 27(8):446-451.
(135) Schneider A, Kirchhoff T, Meinhardt
G, Gissmann L. Repeated evaluation of human papillomavirus
16
status in cervical swabs of young women with a history
of normal Papanicolaou smears. Obstetrics & Gynecology
1992; 79(5:( Pt 1):t-8.
(136) Adam E, Berkova Z,
Daxnerova Z, Icenogle J, Reeves WC, Kaufman RH. Papillomavirus
detection: demographic and behavioral characteristics
influencing the identification of cervical disease.
American Journal of Obstetrics & Gynecology 2000;
182(2):257-264.
(137) Becker TM, Wheeler CM, McGough
NS, Parmenter CA, Jordan SW, Stidley CA et al.
Sexually transmitted diseases and other risk factors
for cervical
dysplasia among southwestern Hispanic and non-Hispanic
white women. JAMA 1994; 271(15):1181-1188.
(138)
Donnan SP, Wong FW, Ho SC, Lau EM, Takashi K, Esteve
J. Reproductive and sexual risk factors and human
papilloma virus infection in cervical cancer among
Hong Kong Chinese. International Journal of Epidemiology
1989; 18(1):32-36.
(139) Evans BA, Tasker T, MacRae
KD. Risk profiles for genital infection in women.
Genitourinary Medicine 1993; 69(4):257-261.
(140)
Fasal E, Simmons ME, Kampert JB. Factors associated
wih high and low risk of cervical neoplasia. Journal
of the National Cancer Institute 1981; 66(4):631-636.
(141) Figueroa JP, Ward E, Luthi TE,
Vermund SH, Brathwaite AR, Burk RD. Prevalence of
human papillomavirus
among STD clinic attenders in Jamaica: association
of younger age and increased sexual activity. Sexually
Transmitted Diseases 1995; 22(2):114-118.
(142) Fonck
K, Kidula N, Kirui P, Ndinya-Achola J, Bwayo J,
Claeys P et al. Pattern of sexually transmitted diseases
and risk factors among women attending an STD referral
clinic in Nairobi, Kenya. Sexually Transmitted
Diseases
2000; 27(7):417-423.
(143) Hildesheim A, Brinton LA, Mallin
K, Lehman HF, Stolley P, Savitz DA et al. Barrier
and spermicidal contraceptive methods and risk of
invasive cervical cancer. Epidemiology 1990; 1(4):266-272.
(144) Hillman RJ, Ryait BK, Botcherby
M, Taylor-Robinson D. Human papillomavirus DNA in
the urogenital tracts
of men with gonorrhoea, penile warts or genital
dermatoses. Genitourinary Medicine 1993; 69(3):187-192.
(145)
Hippelainen MI, Hippelainen M, Saarikoski S, Syrjanen
K. Clinical course and prognostic factors of human
papillomavirus infections in men. Sexually Transmitted
Diseases 1994; 21(5):272-279.
(146) Ho GY, Kadish
AS, Burk RD, Basu J, Palan PR, Mikhail M et al.
HPV 16 and cigarette smoking as risk factors for
high-grade
cervical intra-epithelial neoplasia. International
Journal of Cancer 1998; 78(3):281-285.
(147) Juarez-Figueroa
LA, Wheeler CM, Uribe-Salas FJ, Conde-Glez CJ,
Zampilpa-Mejia LG, Garcia-Cisneros S et al. Human
papillomavirus:
a highly prevalent sexually transmitted disease
agent among female sex workers from Mexico City.
Sexually
Transmitted Diseases 2001; 28(3):125-130.
(148) Kataja
V, Syrjanen S, Yliskoski M, Hippelinen M, Vayrynen
M, Saarikoski S et al. Risk factors associated
with cervical human papillomavirus infections: a
case-control
study. American Journal of Epidemiology 1993; 138(9):735-745.
(149) Kjaer SK, de Villiers EM, Dahl
C, Engholm G, Bock JE, Vestergaard BF et al. Case-control
study
of risk factors for cervical neoplasia in Denmark.
I: Role of the "male factor" in women with
one lifetime sexual partner. International Journal
of Cancer 1991; 48(1):39-44.
(150) Kjaer SK, van
den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman
ME et al. Determinants for genital human papillomavirus
(HPV) infection in 1000 randomly chosen young Danish
women with normal Pap smear: are there different
risk profiles for oncogenic and nononcogenic HPV
types? Cancer Epidemiology, Biomarkers & Prevention
1997; 6(10):799-805.
(151) Kjaer SK, Svare EI, Worm
AM, Walboomers JM, Meijer CJ, van den Brule AJ.
Human papillomavirus infection in Danish female sex
workers.
Decreasing prevalence with age despite continuously
high sexual activity. Sexually Transmitted Diseases
2000; 27(8):438-445.
(152) Kotloff KL, Wasserman
SS, Russ K, Shapiro S, Daniel R, Brown W et al.
Detection of genital human papillomavirus and associated
cytological
abnormalities among college women. Sexually Transmitted
Diseases 1998; 25(5):243-250.
(153) Mayaud P, Gill
DK, Weiss HA, Uledi E, Kopwe L, Todd J et al. The
interrelation of HIV, cervical human papillomavirus,
and neoplasia among antenatal clinic attenders
in Tanzania. Sexually Transmitted Infections 2001;
77(4):248-254.
(154) Munoz N, Bosch FX, de Sanjose
S, Vergara A, del Moral A, Munoz MT et al. Risk factors
for cervical intraepithelial neoplasia grade III/carcinoma
in situ in Spain and Colombia. Cancer Epidemiology,
Biomarkers & Prevention 1993; 2(5):423-431.
(155)
Parazzini F, Negri E, La Vecchia C, Fedele L. Barrier
methods of contraception and the risk of cervical
neoplasia. Contraception 1989; 40(5):519-530.
(156)
Peters RK, Thomas D, Hagan DG, Mack TM, Henderson
BE. Risk factors for invasive cervical cancer among
Latinas and non-Latinas in Los Angeles County.
Journal of the National Cancer Institute 1986; 77(5):1063-1077.
(157) Sellors J, Mahoney JB, Kacqorowski
J, et al. Prevalence and predictors of human papillomavirus
infection in women in Ontario, Canada. Can Med
Assoc
J 2000; 163:503-508.
(158) Shlay JC, McGill WL, Masloboeva
HA, Douglas JM, Jr. Pap smear screening in an urban
STD clinic. Yield of screening and predictors of
abnormalities. Sexually Transmitted Diseases 1998;
25(9):468-475.
(159) Slattery ML, Overall JC, Jr.,
Abbott TM, French TK, Robison LM, Gardner J. Sexual
activity, contraception, genital infections, and
cervical cancer: support for a sexually transmitted
disease hypothesis. American Journal of Epidemiology
1989; 130(2):248-258. (160) Svare EI, Kjaer SK, Worm
AM, Osterlind A, Moi H, Christensen RB et al. Risk
factors for HPV infection in women from sexually
transmitted disease clinics: comparison between
two areas with different cervical cancer incidence.
International
Journal of Cancer 1998; 75(1):1-8.
(161) Syrjanen
K, Vayrynen M, Castren O, Yliskoski M, Mantyjarvi
R, Pyrhonen S et al. Sexual behaviour of women
with human papillomavirus (HPV) lesions of the
uterine cervix. British Journal of Venereal Diseases
1984;
60(4):243-248.
(162) Thomas DB, Ray RM, Pardthaisong
T, Chutivongse S, Koetsawang S, Silpisornkosol
S et al. Prostitution, condom use, and invasive squamous
cell cervical cancer in Thailand. American Journal
of Epidemiology 1996; 143(8):779-786.
(163) Wang
PD LR. Risk factors for cervical intraepithelial
neoplasia in Taiwan. Gynecologic Oncology 1996; 62:10-18.
(164) Wen LM, Estcourt CS, Simpson
JM, Mindel A. Risk factors for the acquisition of
genital warts:
are condoms protective? Sexually Transmitted Infections
1999; 75(5):312-316.
(165) Young TK, McNicol P, Beauvais
J. Factors associated with human papillomavirus
infection detected by polymerase chain reaction among
urban
Canadian aboriginal and non-aboriginal women.[comment].
Sexually Transmitted Diseases 1997; 24(5):293-298.
(166) Zondervan KT, Carpenter LM, Painter
R, Vessey MP. Oral contraceptives and cervical cancer--further
findings from the Oxford Family Planning Association
contraceptive study. British Journal of Cancer 1996;
73(10):1291-1297.
(167) Bleeker MC, Hogewoning CJ,
van den Brule AJ, Voorhorst FJ, Van Andel RE, Risse
EK et al. Penile lesions and human papillomavirus
in male sexual partners of women with cervical
intraepithelial neoplasia. Journal of the American
Academy of Dermatology
2002; 47(3):351-357.
(168) Hogewoning CJ, Bleeker
MC, Van den Brule AJ, Voorhorst FJ, Snijders PJ,
Berkhof J et al. Condom use promotes regression
of cervical intraepithelial neoplasia and clearance
of human papillomavirus: a randomized clinical
trial.
Int.J.Cancer 107, 811-816. 2003.
(169) Manhart LE,
Koutsky LA. Do condoms prevent genital HPV infection,
external genital warts, or cervical neoplasia?
A meta-analysis. Sexually Transmitted Diseases 2002;
29(11):725-735.
(170) Sokal DC, Hermonat PL. Inactivation
of papillomavirus by low concentrations of povidone-iodine.
Sexually Transmitted Diseases 1995; 22(1):22-24.
(171) Howett MK, Neely EB, Christensen
ND, Wigdahl B, Krebs FC, Malamud D et al. A broad-spectrum
microbicide
with virucidal activity against sexually transmitted
viruses. Antimicrobial Agents & Chemotherapy
1999; 43(2):314-321.
(172) Christensen ND, Reed CA,
Culp TD, Hermonat PL, Howett MK, Anderson RA et al.
Papillomavirus microbicidal activities of high-molecular-weight
cellulose sulfate, dextran sulfate, and polystyrene
sulfonate. Antimicrobial Agents & Chemotherapy
2001; 45(12):3427-3432.
(173) Coutlee F, Voyer H.
Effect of nonionic detergents on amplification
of human papillomavirus DNA with consensus primers
MY09
and MY11. Journal of Clinical Microbiology 1998;
36(4):1164.
(174) Anwar H, Coetzee N, Blanchard
K, Dangor Y, de Kock A, Friedland B et al. A randomized,
placebo-controlled double-blind expanded safety
trial
of carraguard microbicide gel in South Africa:
RTI/STI at Baseline and Follow-up. [Abstract] May
12-15,
2002.Antwerp, Belgium.
(175) Celentano DD, Klassen
AC, Weisman CS, Rosenshein NB. The role of contraceptive
use in cervical cancer: the Maryland Cervical Cancer
Case-Control Study. American Journal of Epidemiology
1987; 126(4):592-604.
(176) Fairley CK, Gay NJ, Forbes
A, Abramson M, Garland SM. Hand-genital transmission
of genital warts? An analysis of prevalence data.
Epidemiology & Infection 1995; 115(1):169-176.
(177) Collins S, Mazloomzadeh S, Winter
H, Blomfield P, Bailey A, Young LS et al. High incidence
of cervical human papillomavirus infection in women
during their first sexual relationship. BJOG: an
International Journal of Obstetrics & Gynaecology
2002; 109(1):96-98.
(178) Lowy DR, Frazer IH. Chapter
16: Prophylactic human papillomavirus vaccines.
Journal of the National Cancer Institute Monographs
2003;(31):111-116.
(179) Kulasingam SL, Myers ER. Potential
health and economic impact of adding a human papillomavirus
vaccine to screening programs. JAMA 2003; 290(6):781-789.
(180) Sanders GD, Taira AV. Cost-effectiveness
of a potential vaccine for human papillomavirus.
Emerging
Infectious Diseases 2003; 9(1):37-48.
(181) Koutsky
LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez
FB et al. A controlled trial of a human papillomavirus
type 16 vaccine. New England Journal of Medicine
2002; 347(21):1645-1651.
(182) Kahn JA, Rosenthal
SL, Hamann T, Bernstein DI. Attitudes about human
papillomavirus vaccine in young women. International
Journal of STD & AIDS 2003; 14(5):300-306.
(183)
Kiviat NB, Critchlow CW, Holmes KK, Kuypers J,
Sayer J, Dunphy C et al. Association of anal dysplasia
and human papillomavirus with immunosuppression
and
HIV infection among homosexual men. AIDS 1993;
7(1):43-49.
(184) Swan J, Breen N, Coates RJ, Rimer
BK, Lee NC. Progress in cancer screening practices
in the United
States: results from the 2000 National Health Interview
Survey. Cancer 2003; 97(6):1528-1540.
(185) Seeff
LC, McKenna MT. Cervical cancer mortality among foreign-born
women living in the United States, 1985 to 1996.
Cancer Detection & Prevention 2003; 27(3):203-208.
(186) Saslow D, Runowicz CD, Solomon
D, Moscicki AB, Smith RA, Eyre HJ et al. American
Cancer Society
guideline for the early detection of cervical neoplasia
and cancer. Ca: a Cancer Journal for Clinicians
2002; 52(6):342-362.
(187) American College of Obstetricians
and Gynecologists. Cervical Cytology Screening.
Clinical Management Guidelines for Obstetrician-Gynecologists.
ACOG Practice Bulletin, No. 45. August, 2003. 2003.
<
Last Segment: Prevention | Next
Segment: Front Page > |